The health and economic burden of haemophilia in Belgium: A rare, expensive and challenging disease

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Henrard, Séverine ^a,b   Devleesschauwer, Brecht ^a,c   Beutels, Philippe ^d   Callens, Michael ^e   De Smet, Frank ^e,f   Hermans, Cedric ^b   Speybroeck, Niko ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e National Alliance of Christian Sickness Funds   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Burden; Costs; Disability adjusted life year; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; BELGIUM; CHILD; COHORT ANALYSIS; CONSULTATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE SEVERITY; DYING; HEALTH ECONOMICS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MORTALITY; PATIENT TRANSPORT; PHYSIOTHERAPY PRACTICE; PREMATURE MORTALITY; QUALITY OF LIFE; SHORT FORM 36; UNEMPLOYMENT; WORLD HEALTH ORGANIZATION;

BELGIUM; BLOOD COAGULATION FACTORS; COHORT STUDIES; COST OF ILLNESS; HEMOPHILIA A; HUMANS;

EID: 84899436244     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-39     Document Type: Article

References (44)

1. Modern haemophilia care. Berntorp E, Shapiro AD, Lancet 2012 379 1447 1456 10.1016/S0140-6736(11)61139-2 22456059
2. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M, Blood 2007 110 815 825 10.1182/blood-2006-10-050435 17446349
3. The modern treatment of haemophilia: a narrative review. Franchini M, Blood Transfus 2013 11 178 182 22790275
4. New challenges in hemophilia: long-term outcomes and complications. Young G, Hematology Am Soc Hematol Educ Program 2012 2012 362 368 23233605
5. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Klamroth R, Pollmann H, Hermans C, Faradji A, Yarlas AS, Epstein JD, Ewenstein BM, Haemophilia 2011 17 412 421 10.1111/j.1365-2516.2010.02435.x 21332888
6. Psychological aspects and coping in haemophilic patients: a case-control study. Canclini M, Saviolo-Negrin N, Zanon E, Bertoletti R, Girolami A, Pagnan A, Haemophilia 2003 9 619 624 10.1046/j.1365-2516.2003.00807.x 14511304
7. Confronting the psychological burden of haemophilia. Coppola A, Cerbone AM, Mancuso G, Mansueto MF, Mazzini C, Zanon E, Haemophilia 2011 17 21 27 10.1111/j.1365-2516.2010.02280.x 20579110
8. Past, present and future of hemophilia: a narrative review. Franchini M, Mannucci PM, Orphanet J Rare Dis 2012 7 24 10.1186/1750-1172-7-24 22551339
9. New methodology for estimating the burden of infectious diseases in Europe. Kretzschmar M, Mangen MJ, Pinheiro P, Jahn B, Fevre EM, Longhi S, Lai T, Havelaar AH, Stein C, Cassini A, Kramarz P, PLoS Med 2012 9 1001205 10.1371/journal.pmed.1001205 22529750
10. National plans and strategies on rare diseases in Europe. Taruscio D, Vittozzi L, Stefanov R, Adv Exp Med Biol 2010 686 475 491 10.1007/978-90-481- 9485-8-26 20824461
11. The increasing prevalence of haemophilia. Rosendaal FR, Briet E, Thromb Haemost 1990 63 145 2339353
12. Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigators. Soucie JM, Evatt B, Jackson D, Am J Hematol 1998 59 288 294 10.1002/(SICI)1096-8652(199812)59:4<288::AID- AJH4>3.0.CO;2-I 9840909
13. A study of variations in the reported haemophilia A prevalence around the world. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M, Haemophilia 2010 16 20 32
14. A study of variations in the reported haemophilia B prevalence around the world. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M, Haemophilia 2012 18 91 e94 10.1111/j.1365-2516.2011.02588.x 21649801
15. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR, J Thromb Haemost 2006 4 510 516 16460432
16. Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006. Reitter S, Waldhoer T, Vutuc C, Lechner K, Pabinger I, Haemophilia 2009 15 888 893 10.1111/j.1365-2516.2009. 02029.x 19473415
17. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Murray CJ, Bull World Health Organ 1994 72 429 445 8062401
18. The R Core Team, R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing 2012
19. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, et al. Lancet 2012 380 2197 2223 10.1016/S0140-6736(12)61689-4 23245608
20. Are disability weights universal?WHO/NIH joint project CAR study group. Ustun TB, Saxena S, Rehm J, Bickenbach J, Lancet 1999 354 1306
21. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin AA, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, et al. Lancet 2012 380 2129 2143 10.1016/S0140-6736(12)61680-8 23245605
22. A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch burden of disease group. Melse JM, Essink-Bot ML, Kramers PG, Hoeymans N, Am J Public Health 2000 90 1241 1247 10937004
23. The impact of sport on children with haemophilia. Khair K, Littley A, Will A, von Mackensen S, Haemophilia 2012 18 898 905 10.1111/j.1365-2516.2012. 02857.x 22630612
24. Health-related quality of life of children and adolescents in Germany. Norm data from the German health interview and examination survey (KiGGS). Ravens-Sieberer U, Ellert U, Erhart M, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007 50 810 818 10.1007/s00103-007-0244-4 17514467
25. Physical and mental quality of life in adults with haemophilia in Belgium: the impact of financial issues. Monteiro Carvalhosa A, Henrard S, Lambert C, Hermans C, Haemophilia in press
26. Sf-6d population norms. van den Berg B, Health Econ 2012 21 1508 1512 10.1002/hec.1823 22250070
27. Disability-adjusted life years: a critical review. Anand S, Hanson K, J Health Econ 1997 16 685 702 10.1016/S0167-6296(97)00005-2 10176779
28. Understanding DALYs (disability-adjusted life years). Murray CJ, Acharya AK, J Health Econ 1997 16 703 730 10.1016/S0167-6296(97)00004-0 10176780
29. The friction cost method for measuring indirect costs of disease. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L, J Health Econ 1995 14 171 189 10.1016/0167-6296(94)00044-5 10154656
30. Cleemput I, Neyt M, Van De Sande S, Thiry N, Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE) 2012
31. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Miners A, Haemophilia 2009 15 881 887 10.1111/j.1365-2516.2009.02019.x 19473422
32. Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population. Shapiro AD, Soucie JM, Peyvandi F, Aschman DJ, DiMichele DM, Am J Prev Med 2011 41 324 S331 10.1016/j.amepre.2011.09.021 22099354
33. Burden of disease resulting from hemophilia in the U.S. Siddiqi AE, Ebrahim SH, Soucie JM, Parker CS, Atrash HK, Am J Prev Med 2010 38 482 S488 10.1016/j.amepre.2009.12.016 20331947
34. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM, Haemophilia 2012 18 268 275 10.1111/j.1365-2516.2011.02692.x 22151000
35. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM, Haemophilia 2012 18 276 283 10.1111/j.1365-2516.2011.02713.x 22188641
36. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. Tencer T, Friedman HS, Li-McLeod J, Johnson K, J Manag Care Pharm 2007 13 790 798 18062730
37. Haemophilia care in Europe-a survey of 35 countries. O'Mahony B, Noone D, Giangrande PL, Prihodova L, Haemophilia 2013 19 239 e247 10.1111/hae.12125 23557438
38. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G, Haemophilia 2010 16 256 262 10.1111/j.1365-2516.2009.02122.x 19878331
39. The European rare diseases therapeutic initiative. Fischer A, Borensztein P, Roussel C, PLoS Med 2005 2 243 10.1371/journal.pmed.0020243 16104832
40. Social participation of patients with hemophilia in the Netherlands. Plug I, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR, Van Der Bom JG, Blood 2008 111 1811 1815 10.1182/blood-2007-07-102202 17986664
41. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Henrard S, Speybroeck N, Hermans C, Haematologica 2013 98 1481 1486 10.3324/haematol.2013.084038 23645693
42. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM, J Thromb Haemost 2010 8 269 275 19943875
43. The selection and use of essential medicines. World Health Organization, World Health Organ Tech Rep Ser 2011 965 1 249
44. Making haemophilia a global priority. Lancet 2012 379 1366